Iovance Catches a Tailwind as Rival Stumbles and Pipeline Progress Mounts

Iovance stock surges 71% in six months as FDA rejects rival Replimune's therapy, boosting Amtagvi's melanoma market lead. Q4 revenue hits $87.1M, with pivotal trials ahead.

Iovance Biotherapeutics has hit a fresh 52-week high of $4.35, extending a rally that has seen the stock climb 71% over the past six months. The latest leg higher came as the company’s shares advanced roughly 8.68% in a single session, propelled by a regulatory setback for a key competitor.

The US Food and Drug Administration dealt a blow to Replimune, refusing to approve its experimental therapy RP1 for now. That decision clears the path for Iovance’s Amtagvi, the first FDA-approved T-cell therapy for solid tumors, to operate without immediate competition in the melanoma space. Jefferies analysts have pointed to this as a significant advantage, noting that Iovance now has an open lane to cement its leadership in tumor-infiltrating lymphocyte (TIL) therapies.

The company’s clinical momentum extends beyond skin cancer. Data from a pilot study of Lifileucel in advanced sarcoma showed a 50% response rate, prompting management to plan a pivotal trial for the second quarter of 2026. Iovance also intends to engage the FDA about a potential accelerated approval pathway for that indication. Meanwhile, the next-generation TIL therapy, IOV-5001, is on track for a regulatory filing in the first half of 2026, and progress continues on LN-145 for lung cancer patients.

On the commercial front, Amtagvi generated fourth-quarter 2025 revenue of $87.1 million, contributing to full-year 2025 sales of $264 million — a sequential growth rate of 30%. The company ended the year with $303 million in cash, which management says will fund operations into 2027. Citizens analysts upgraded the stock to “Market Outperform,” citing progress in expanding the clinic network and manufacturing capacity, both critical for scaling the complex, patient-specific cell therapies.

Still, challenges remain. The logistics of producing individualized therapies are costly and intricate, and reimbursement hurdles along with the need for specialized treatment centers have tempered the pace of the commercial rollout. Investors will be watching closely when first-quarter 2026 results are released in May. Analysts forecast a loss of between $0.14 and $0.19 per share on revenue of roughly $81 million, with attention fixed on margin trends and cash burn during this scaling phase.

A shareholder meeting scheduled for June will see a proposal to increase the authorized share count from 500 million to 650 million, a move designed to provide financial flexibility for ongoing clinical development and commercial expansion. The company’s confirmed response rate for Amtagvi patients treated under the current US label stands at approximately 44%, reinforcing the therapy’s clinical value as Iovance navigates this pivotal period of growth.